TechFlow, Nov. 4 — According to GLOBE NEWSWIRE, NASDAQ-listed biopharmaceutical company Propanc Biopharma (PPCB) announced the launch of a strategic acquisition initiative targeting Digital Asset Treasury (DAT) companies whose market valuation is below their net asset value.
The company's management believes that acquiring undervalued DAT entities will help strengthen the balance sheet, diversify assets, and create long-term shareholder value. These DAT companies typically hold significant reserves of mainstream digital assets such as Bitcoin and Ethereum on their balance sheets.
CEO James Nathanielsz stated this is a strategic diversification move aimed at unlocking value for shareholders while continuing to advance its innovative oncology pipeline. The company's board and executive team are currently evaluating potential acquisition targets.
Previous report, Propanc Biopharma announced plans to acquire $100 million worth of Ethereum.
